Seres Therapeutics Stock Forecast, Price & News

Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions

Is Seres Therapeutics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Seres Therapeutics stock.
View analyst ratings for Seres Therapeutics or view top-rated stocks.

How has Seres Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Seres Therapeutics' stock was trading at $2.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MCRB stock has increased by 304.5% and is now trading at $10.68.
View which stocks have been most impacted by COVID-19.

When is Seres Therapeutics' next earnings date?

Seres Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for Seres Therapeutics.

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) released its earnings results on Wednesday, November, 10th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.47) by $1.19. Seres Therapeutics had a negative net margin of 21.79% and a negative trailing twelve-month return on equity of 22.73%. During the same period in the previous year, the firm posted ($0.36) EPS.
View Seres Therapeutics' earnings history.

What price target have analysts set for MCRB?

7 brokerages have issued 12 month price objectives for Seres Therapeutics' stock. Their forecasts range from $7.00 to $32.00. On average, they expect Seres Therapeutics' stock price to reach $20.83 in the next year. This suggests a possible upside of 95.1% from the stock's current price.
View analysts' price targets for Seres Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Seres Therapeutics' key executives?

Seres Therapeutics' management team includes the following people:

• Eric D. Shaff, President, Chief Executive Officer & Director
• Marcus Chapman, Senior Vice President-Operations
• David A. Arkowitz, EVP, Chief Financial & Accounting Officer
• Matthew R. Henn, Chief Scientific Officer & Executive VP
• Barbara McGovern, Vice President-Medical Affairs

Who are some of Seres Therapeutics' key competitors?

Some companies that are related to Seres Therapeutics include Allakos (ALLK), Arvinas (ARVN), Apellis Pharmaceuticals (APLS), Karuna Therapeutics (KRTX), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Zentalis Pharmaceuticals (ZNTL), 23andMe (ME), Arena Pharmaceuticals (ARNA), ACADIA Pharmaceuticals (ACAD), Cytokinetics (CYTK), Insmed (INSM), Galapagos (GLPG), Intra-Cellular Therapies (ITCI) and Arcus Biosciences (RCUS).
View all of MCRB's competitors.

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Who are Seres Therapeutics' major shareholders?

Seres Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.37%), Janus Henderson Group PLC (4.72%), Two Sigma Investments LP (1.09%), Geode Capital Management LLC (1.04%), Sumitomo Mitsui Trust Holdings Inc. (0.95%) and Nikko Asset Management Americas Inc. (0.95%).
View institutional ownership trends for Seres Therapeutics.

Which major investors are selling Seres Therapeutics stock?

MCRB stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., BlackRock Inc., Goldman Sachs Group Inc., Geode Capital Management LLC, Millennium Management LLC, Principal Financial Group Inc., and LPL Financial LLC.
View insider buying and selling activity for Seres Therapeutics or view top insider-selling stocks.

Which major investors are buying Seres Therapeutics stock?

MCRB stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Voloridge Investment Management LLC, Janus Henderson Group PLC, SG Americas Securities LLC, Two Sigma Advisers LP, Lion Point Capital LP, Hudson Bay Capital Management LP, and UBS Group AG.
View insider buying and selling activity for Seres Therapeutics or or view top insider-buying stocks.

How do I buy shares of Seres Therapeutics?

Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seres Therapeutics' stock price today?

One share of MCRB stock can currently be purchased for approximately $10.68.

How much money does Seres Therapeutics make?

Seres Therapeutics has a market capitalization of $980.96 million and generates $33.22 million in revenue each year. The biotechnology company earns $-89.13 million in net income (profit) each year or ($0.38) on an earnings per share basis.

How many employees does Seres Therapeutics have?

Seres Therapeutics employs 155 workers across the globe.

What is Seres Therapeutics' official website?

The official website for Seres Therapeutics is www.serestherapeutics.com.

Where are Seres Therapeutics' headquarters?

Seres Therapeutics is headquartered at 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139.

How can I contact Seres Therapeutics?

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at (617) 945-9626 or via email at [email protected].